



PRESS RELEASE

21 May 2025 12:00:00 CEST

AcouSort strengthens Central European collaboration with new order

AcouSort AB today announced it has received a second order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's technology for separation of cells in body fluids.

"This is a great example of a collaboration that fits perfectly with our long-term strategy. We are excited by the first results shared from the evaluations and hope to share additional information about the project as the test program moves forward," said AcouSort CEO Torsten Freltoft.

The collaboration was originally initiated in mid-autumn 2024 by an order of an evaluation kit that was delivered to the partner before Christmas. The project has now continued with an order of additional separation modules to continue the process of evaluating the broader feasibility of AcouSort's technology. Being able to provide AcouSort technology in an easily accessible way is an important step in building long-term collaborations with OEM potential.

"The company has been working actively with the evaluation kit acquired during autumn, and we are excited that the evaluation has shown promising results and that the partner now is ready to order additional modules to continue the exploration," said Torsten Freltoft.

The additional units are being delivered to the customer in May.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).